Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.38 |
| ▸ | MC4R | P32245 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CHKA | P35790 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | RAD52 | P43351 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ERN1 | O75460 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18351064 | 1.00 | PAOX (0.38) | PAOXMC4RSIGMAR1ALDH1A1LMNA | |
| SCHEMBL1655253 | 1.00 | PAOX (0.38) | PAOXMC4RSIGMAR1ALDH1A1LMNA | |
| SCHEMBL27020232 | 0.91 | PAOX (0.33) | PAOXMC4RSIGMAR1ALDH1A1HTR1A | |
| Acetic Acid SCHEMBL6625112 | 0.89 | PAOX (0.44) | PAOXMC4RALDH1A1CYP1A2TDP1 | |
| SCHEMBL28374092 | 0.86 | — | — | |
| SCHEMBL24335650 | 0.84 | HSD17B10 (0.41) | PAOXSIGMAR1ALDH1A1LMNATSHR | |
| SCHEMBL2561626 | 0.80 | DRD2 (0.39) | SIGMAR1MEN1KMT2A | |
| SCHEMBL4072907 | 0.80 | L3MBTL1 (0.39) | SIGMAR1ALDH1A1RAD52KMT2A | |
| SCHEMBL4067143 | 0.80 | CACNA2D1 (0.43) | SIGMAR1 | |
| SCHEMBL29300025 | 0.79 | SMN1; SMN2 (0.35) | ALDH1A1TDP1MEN1RAD52KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090238768-A1 | MULTIMERIC MAGNETIC RESONANCE CONTRAST AGENTS | AXELSSON OSKAR | 2009-09-24 | — | — | US | disclosed |
| US-20080292551-A1 | Method to Produce Hyperpolarised Carboxylates | GE HEALTHCARE AS (NO) | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090238768-A1 | MULTIMERIC MAGNETIC RESONANCE CONTRAST AGENTS | MAG, MSR1, FABP7 | PAOX 989/4885MC4R 2486/4885SIGMAR1 927/4885 |
| US-20080292551-A1 | Method to Produce Hyperpolarised Carboxylates | PAM, OAT, TSPO | PAOX 244/4885MC4R 815/4885SIGMAR1 94/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.